Personalis said the US Centers for Medicare and Medicaid Services expanded coverage for its NeXT Personal minimal residual disease (MRD) test to include monitoring response to neoadjuvant treatments in patients with stages II to III triple-negative or HER2-positive breast cancer. The company said the decision was supported by evidence from the PREDICT-DNA prospective clinical study. The update marks the fourth Medicare coverage decision for Personalis’ whole-genome sequencing-based, tumor-informed laboratory-developed assay, following prior Medicare coverage for immunotherapy monitoring across late-stage solid tumors, and recurrence monitoring in stages II to III breast cancer and in stages I to III non-small cell lung cancer. Personalis CEO Chris Hall framed the development as a step toward using ultrasensitive MRD measurements for active treatment management across patients’ clinical journeys, potentially widening adoption beyond initial covered indications.